Regeneron Pharmaceuticals is seeing a modest reset in fair value estimates, with one updated model lifting the figure ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ranks among the most profitable biotech stocks to buy now. On April 10, Piper ...

Longleaf Partners, managed by Southeastern Asset Management, released its fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. The Fund returned 3.35% in the quarter, ...

Regeneron Pharmaceuticals (NASDAQ:REGN) shares witnessed a notable 19% decline on Friday, May 30, in the wake of the unexpected failure of itepekimab, its chronic obstructive pulmonary disease (COPD) ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...

Regeneron Pharmaceuticals, Inc. REGN announced a collaboration agreement with private company Tessera Therapeutics, Inc. for the latter’s TSRA-196. Both companies will jointly develop Tessera’s lead ...

We recently published a list of 10 Best Stocks to Buy and Hold For 2025. In this article, we are going to take a look at where Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) stands against other best ...

Regeneron (REGN) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook gives a ...

Biotech company Regeneron (NASDAQ:REGN) will be reporting earnings this Wednesday morning. Here’s what to expect. Regeneron ...

Regeneron Pharmaceuticals continues to show strong growth, driven by Dupixent's FDA approval for COPD and Eylea HD's market resilience against biosimilars. Q3 earnings beat expectations with $3.72 ...